Pharmacokinetics and metabolism of oral midazolam in preterm infants. - Wikidata - wikimedia - TriplyDB

Pharmacokinetics and metabolism of oral midazolam in preterm infants.

Pharmacokinetics and metabolism of oral midazolam in preterm infants.

http://www.wikidata.org/entity/Q35803591

about

Developmental pharmacokinetics in pediatric populations Clinical pharmacology of midazolam in neonates and children: effect of disease-a review Ontogeny of midazolam glucuronidation in preterm infants.Ontogeny of human hepatic and intestinal transporter gene expression during childhood: age matters.Pain management in newborns.Paediatric pharmacokinetics: key considerations.Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants Anesthesia and analgesia in the NICU.Immunohistochemical markers of CYP3A4 and CYP3A7: a new tool towards personalized pharmacotherapy of hepatocellular carcinoma.Drugs of choice for sedation and analgesia in the neonatal ICU.Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults Optimizing pediatric dosing: a developmental pharmacologic approach.Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children.Ontogeny of oral drug absorption processes in children.Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.Pediatric drug development: formulation considerations.Prediction of glucuronidated drug clearance in pediatrics (≤5 years): An allometric approach.Challenges Associated with Route of Administration in Neonatal Drug Delivery.Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions.Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling.Drug-Induced Liver Injury in Children: Clinical Observations, Animal Models, and Regulatory Status.Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug.A Two-way Randomized Cross-over Pharmacokinetic and Pharmacodynamic Study of an Innovative Oral Solution of Midazolam (ADV6209).First-Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates.Response to: “Prediction of Voriconazole Non-Linear Pharmacokinetics Using a Paediatric Physiologically Based Pharmacokinetic Modelling Approach”

P2860

Q27002933-37AAD3BD-6F02-4817-8005-CCC0F9E3AC20 Q27006333-F0082DE0-5EBB-4B0D-9C8B-4EE4B959899F Q33587843-7A643736-FE54-4615-8DCB-6B5B6913F990 Q33942993-50DE36EA-A38F-440A-9594-C3D15727EB07 Q34625140-11B40FC5-13C6-411A-87DD-317E34EDBDAA Q35135940-D4ED29D6-F48B-4071-9EB7-644C949814D8 Q35867330-E8934BDF-5F3F-4D5D-9CFA-CE3E97534334 Q36730497-9DFC8824-7398-4A60-9A07-49E42C38AE1E Q37067431-5B79A163-6B1E-4C44-A8A6-50671ABEE13D Q37144585-0EBECA1D-BE5F-42A6-8AE7-6618D2122359 Q37378093-3AEF3957-6EA2-4654-BA37-DF4B005ABC1D Q37498862-9D69875D-B807-42F4-BF3B-0D8ECB47BA3B Q37872786-5CA22DFF-BEF6-49B4-8A29-D2DECCFA3933 Q38017723-AA3AFE18-9AD7-486B-B067-E4C4754F2574 Q38086777-4062785D-EE72-49F0-91B1-25658E4F009F Q38183868-0B960AEE-C995-4356-BEDB-B60FA9BBC748 Q38187348-72A19FFF-977D-48EE-AF33-4B791DA59CB7 Q38561363-4CFFBA01-B98D-4BEE-80A8-93BF25C22421 Q39038877-DEAF618B-4820-4214-A36E-2DFEA3E1F164 Q40772216-8750A9B1-5D24-47F9-93D1-3C34FBEEF264 Q47781069-37DFD428-D53F-408A-BE3E-34DE120BD7DA Q48151911-0724460F-1737-4FCF-9E6B-A726A40B6D9E Q48333229-68273B52-DCDD-4143-A18D-817054AAB2AF Q55454780-1269AEC0-DBE5-49C7-9BED-A26B0BFB2524 Q57730438-5D7B4B11-3966-4D49-8E74-554655F80548

P2860

Pharmacokinetics and metabolism of oral midazolam in preterm infants.

http://www.wikidata.org/entity/Q35803591

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

Pharmacokinetics and metabolism of oral midazolam in preterm infants.

@ast

Pharmacokinetics and metabolism of oral midazolam in preterm infants.

@en

type

label

Pharmacokinetics and metabolism of oral midazolam in preterm infants.

@ast

Pharmacokinetics and metabolism of oral midazolam in preterm infants.

@en

prefLabel

Pharmacokinetics and metabolism of oral midazolam in preterm infants.

@ast

Pharmacokinetics and metabolism of oral midazolam in preterm infants.

@en

P1433

Q35803591-FECF5DAE-58EC-4C93-960D-AF79C4219312

P1476

Q35803591-B3B0E884-E3BC-4D80-BF7C-3E93AE3A5D42

P2093

Q35803591-36687241-FDBF-4A04-A09E-024F16518D12

Q35803591-552E7334-CA3D-4717-9336-9C21D9F968C0

Q35803591-60B44B20-38EB-43B3-9965-3E371786C8DB

Q35803591-80AF94AA-21A5-42EF-AD0B-92BF8F28EE12

Q35803591-D56244B6-A8F1-4C7C-A7FA-4B07AD70BBF2

Q35803591-FF2BCF88-6898-4190-81E9-5821BC7EB3F2

P2860

Q35803591-0B0FDE8B-C320-40C5-8BE1-F82BF3C36891

Q35803591-1DF386B1-6ABC-4250-96B6-B946C2B04E18

Q35803591-1F9864E6-10E5-43B0-9871-7776CFA0D433

Q35803591-2731C7A7-7C7F-45C5-8783-584186E0729E

Q35803591-2A4F0555-37CD-49E5-87FD-0C458FE05E7A

Q35803591-3440F638-A70A-42B7-B6C2-891EF9A2EA0A

Q35803591-4BE4315C-7661-4A70-92F4-A8860F05828A

Q35803591-81B493A2-662E-40B8-BD33-4B5C9931B46E

Q35803591-861E0860-E73C-457E-B9E6-7A3D01C3BC4C

Q35803591-9737C7C1-02BA-49CD-A649-5E1D536D7D28

P304

Q35803591-20A04EC3-51CF-4436-939D-6D3EB8309EB3

P31

Q35803591-B9C6F6BF-A010-49AD-A591-CAEAD571E8C9

P356

Q35803591-AE5CB221-CC2A-422E-9001-4C3DEF2EA758

P407

Q35803591-791A5D59-67EE-4C81-91B7-C1FA44D60887

P433

Q35803591-A580FB39-FD05-4D39-9AED-D4EE6C5B3A6E

P478

Q35803591-78370B92-0EE5-4835-BBFD-CD160CBEBC6A

P577

Q35803591-4107B7D3-BF08-46A6-BDEE-A75C8683F5BB

P5875

Q35803591-2D67238A-CB85-4492-A51E-7A474A5CDC7C

P698

Q35803591-5AC24662-B0D3-41C1-AEB1-0449564A46F9

P921

Q35803591-0269E3B3-8692-4252-A9FC-89E92F956F3F

P932

Q35803591-F5F12A79-850E-404F-8535-8D644379C807

P356

J.1365-2125.2002.01223.X

P1433

British Journal of Clinical Pharmacology

P1476

Pharmacokinetics and metabolism of oral midazolam in preterm infants.

@en

P2093

D J Murry

http://www.w3.org/2001/XMLSchema#string

G L Kearns

http://www.w3.org/2001/XMLSchema#string

J N van den Anker

http://www.w3.org/2001/XMLSchema#string

S M Abdel-Rahman

http://www.w3.org/2001/XMLSchema#string

S N de Wildt

http://www.w3.org/2001/XMLSchema#string

W C J Hop

http://www.w3.org/2001/XMLSchema#string

P2860

Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis

Cytochrome P450 3A: ontogeny and drug disposition.

Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth.

Clinical pharmacokinetics of sedatives in neonates.

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.

Reversed-phase ion-pair HPLC method for the direct analysis of 1-OH midazolam glucuronide in human serum.

Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics.

First-pass metabolism of midazolam by the human intestine.

Population pharmacokinetics of midazolam in neonates.

Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

P304

390-392

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2125.2002.01223.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2002-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11400747

http://www.w3.org/2001/XMLSchema#string

P698

11966671

http://www.w3.org/2001/XMLSchema#string

P921

P932

1874268

http://www.w3.org/2001/XMLSchema#string